Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Peter M. Voorhees, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J. Costa, MD PhD, Yana Lutska, PharmD, Padma Bobba, Daniela Hoehn, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137105

Published: 2020

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-137109

Published: 2020

Journal Articles

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, MD, Anita D'Souza, MD MS, Nina Shah, MD, Peter M. Voorhees, MD, Ben Buelow, MD PhD, Ravi Vij, MBBS, Shaji K. Kumar, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-139893

Published: 2020

Journal Articles

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Ben Buelow, MD PhD, Anita D'Souza, MBBS, Cesar Rodriguez, MD, Ravi Vij, MBBS, Rajneesh Nath, MD, Melinda Snyder, MS, Duy Pham, MBA, Ashwin Patel, PhD, Suhasini Iyer, PhD

Blood (2019) 134 (Supplement_1): 1874.

https://doi.org/10.1182/blood-2019-123220

Published: 2019

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J Costa, MD PhD, Yana Lutska, PharmD, Daniela Hoehn, MDPhD, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 151.

https://doi.org/10.1182/blood-2018-151

Published: 2018

Journal Articles

Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual

Cesar Rodriguez, MD, Roy Ervin Strowd III, MD, David D Grier

Blood (2017) 130 (Supplement 1): 5410.

https://doi.org/10.1182/blood.V130.Suppl_1.5410.5410

Published: 2017

Journal Articles

Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Peter M. Voorhees, MD, Luciano J. Costa, MD PhD, Brandi Reeves, MD, Nitya Nathwani, Cesar Rodriguez, MD, Yana Lutska, Laura Hydutsky, Huiling Pei, Jon Ukropec, Ming Qi, Thomas Lin, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 1879.

https://doi.org/10.1182/blood.V130.Suppl_1.1879.1879

Published: 2017

Journal Articles

Low Pre-Transplant Vitamin D Levels Predict an Inferior Survival in Patients with Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Vaidya Rakhee, Shane Ahlers, Cesar Rodriguez, MD, Zanetta S. Lamar, MD, David D Hurd, MD

Blood (2016) 128 (22): 5655.

https://doi.org/10.1182/blood.V128.22.5655.5655

Published: 2016

Journal Articles

The Experience in Treating Elders with AML Using High-Dose AraC.

Cesar Rodriguez, MD, Roger Herzig, MD, Geoffrey P. Herzig, MD

Blood (2016) 128 (22): 5201.

https://doi.org/10.1182/blood.V128.22.5201.5201

Published: 2016

Journal Articles

A Novel Evidence That PNH Affected Cells Residing in Bone Marrow (BM) Due to Impaired Incorporation of CXCR4 and VLA-4 Into Membrane Lipid Rafts Show Defective SDF-1- and VCAM-1-Mediated Retention in BM What Leads to Their Increased Motility and Impaired Interaction with the BM Stem Cell Niches

Kasia Mierzejewska, MS, Cesar Rodriguez, MD, Vivek R. Sharma, MD, FRCPA, Magdalena Kucia, Ph.D., Jaroslaw P. Maciejewski, MD, PhD, Janina Ratajczak, MD, PhD, Mariusz Z Ratajczak, MD, PhD

Blood (2012) 120 (21): 1256.

https://doi.org/10.1182/blood.V120.21.1256.1256

Published: 2012

Journal Articles

Multiple Myeloma Variant with Ascites and Cytoplasmic Crystalline Granules in Plasma Cells

Cesar Rodriguez, MD, Anthony Janckila, Sylvia Potenziani, MD, Vivek R. Sharma, MD, FRCPA

Blood (2011) 118 (21): 5088.

https://doi.org/10.1182/blood.V118.21.5088.5088

Published: 2011

NARROW

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual

Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Low Pre-Transplant Vitamin D Levels Predict an Inferior Survival in Patients with Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

The Experience in Treating Elders with AML Using High-Dose AraC.

A Novel Evidence That PNH Affected Cells Residing in Bone Marrow (BM) Due to Impaired Incorporation of CXCR4 and VLA-4 Into Membrane Lipid Rafts Show Defective SDF-1- and VCAM-1-Mediated Retention in BM What Leads to Their Increased Motility and Impaired Interaction with the BM Stem Cell Niches

Multiple Myeloma Variant with Ascites and Cytoplasmic Crystalline Granules in Plasma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only